how long does tirzepatide delay gastric emptying Effect of on in healthy participants (A,B) Does Tirzepatide Fatigue Go Away?

Description

Semaglutide trial shows promise for schizophrenia, prediabetes, and obesity Summary of the HISTORI Randomized Clinical Trial The HISTORI trial, published in *JAMA Psychiatry* on September 3, 2025 (doi:10.1001/jamapsychiatry.2025.2332), is a multicenter, double-blind, placebo-controlled randomized clinical trial evaluating the efficacy and safety of once-weekly subcutaneous semaglutide (a glucagon-like peptide-1 receptor agonist) as an adjunct to second-generation antipsychotic treatment in adults with schizophrenia spectrum disorders, prediabetes (HbA1c 5.7%-6.4%), and overweight/obesity (BMI 27 kg/m)

Sin embargo, aproximadamente el 10-15% de los pacientes experimentan una prdida de peso inferior al 5% del peso corporal inicial, considerada insuficiente segn el etiquetado de la FDA, que recomienda evaluar la respuesta despus de 12 semanas en la dosis de mantenimiento

Alongside tirzepatide treatment, maintaining a healthy diet, engaging in regular physical activity, and having frequent provider check-ins will aid in achieving optimal results

These outcomes suggest that tirzepatide could be especially beneficial for individuals with significant weight loss goals or those who have found it challenging to control their diabetes with other medications